Passage Bio, Inc. (PASG) Q4 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Passage Bio Board Quarter and Full Year 2022 Financial and Operating Results Conference Call. At this time, all participants are in listen-only mode. Following the formal remarks, we will open the call-out for your questions. Please be advised that this call is being recorded at the company's request. Now, I'd like to turn it over to Stuart Henderson, Vice President of Corporate Development and Investor Relations. Stuart, please proceed. Thank you, Operator. This morning, we issued a press release that outlines the topics we plan to discuss today. This release is available on the Passage Bio website under the Press Releases and Statements section of Investors & News. On today's call, Chief Executive Officer Will Chu will review our fourth quarter 2022 and recent business highlights. Mark Foreman, our Chief Medical Officer, will review our clinical programs, and Simona King, our Chief Financial Officer, will review our fourth quarter and full year 2022 financial results. Before we begin, please note that today's call may include a number of forward-looking statements. These forward-looking statements are based on assumptions that are subject to risks and uncertainties that could cause the company's actual results to differ significantly from those suggested by these statements. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Please refer to the company's filings with the SEC for information concerning risk factors that could cause its actual results to differ materially from expectations including any forward-looking statements made on this call. Except as required by law, the company disclaims any obligation to publicly update or revise any forward-looking statements to acco...